Abstract
Introduction: preeclampsia is defined as hypertension during pregnancy and this increase in blood pressure can lead to serious and unwanted decompensations for both the mother and the fetus. It has been shown that among the factors that lead to maternal death, PE ranks third, not being surpassed only by hemorrhages and thrombosis.Objective: to determine the role of low molecular weight heparin in preeclampsia and fetal growth restriction syndrome.Method: a systematic review of the literature was carried out addressing the analysis of the efficacy and safety of low molecular weight heparin in the treatment of preeclampsia. The articles were searched in the following databases such as Pubmed, Elsevier in the following languages: English, Spanish and Portuguese, from the last 20 years.Results: 16 studies that met the inclusion criteria were included and 25,261 pregnant women were analyzed.Conclusion: the analysis carried out shows that the efficacy of using LMWH in preeclampsia and fetal growth restriction syndrome can be an option in the treatment and prevention, however a great heterogeneity was detected in the results of the trials, which does not yet allow its use in medical practice
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: SCT Proceedings in Interdisciplinary Insights and Innovations
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.